Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $7.7 million.

  • Pharma's Non-Current Assets rose 2647.49% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year increase of 2647.49%. This contributed to the annual value of $5.9 million for FY2025, which is 558.33% down from last year.
  • According to the latest figures from Q3 2025, Pharma's Non-Current Assets is $7.7 million, which was up 2647.49% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Pharma's Non-Current Assets ranged from a high of $12.4 million in Q1 2021 and a low of $5.8 million during Q2 2025
  • Its 5-year average for Non-Current Assets is $9.3 million, with a median of $10.6 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 4214.9% in 2024, then skyrocketed by 2647.49% in 2025.
  • Quarter analysis of 5 years shows Pharma's Non-Current Assets stood at $12.1 million in 2021, then dropped by 11.08% to $10.7 million in 2022, then fell by 28.37% to $7.7 million in 2023, then decreased by 21.48% to $6.0 million in 2024, then increased by 28.41% to $7.7 million in 2025.
  • Its last three reported values are $7.7 million in Q3 2025, $5.8 million for Q2 2025, and $5.9 million during Q1 2025.